[go: up one dir, main page]

RU95112842A - ANTITUMER COMPOSITION CONTAINING TAXANA DERIVATIVES - Google Patents

ANTITUMER COMPOSITION CONTAINING TAXANA DERIVATIVES

Info

Publication number
RU95112842A
RU95112842A RU95112842/14A RU95112842A RU95112842A RU 95112842 A RU95112842 A RU 95112842A RU 95112842/14 A RU95112842/14 A RU 95112842/14A RU 95112842 A RU95112842 A RU 95112842A RU 95112842 A RU95112842 A RU 95112842A
Authority
RU
Russia
Prior art keywords
composition according
derivatives
epidophyllotoxins
antimetabolites
procarbazine
Prior art date
Application number
RU95112842/14A
Other languages
Russian (ru)
Other versions
RU2131250C1 (en
Inventor
Биссери Мари-Кристин
Original Assignee
Рон-Пуленк Роре С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9213525A external-priority patent/FR2697752B1/en
Application filed by Рон-Пуленк Роре С.А. filed Critical Рон-Пуленк Роре С.А.
Publication of RU95112842A publication Critical patent/RU95112842A/en
Application granted granted Critical
Publication of RU2131250C1 publication Critical patent/RU2131250C1/en

Links

Claims (13)

1. Противоопухолевая композиция, содержащая комбинации производных таксана с веществом, терапевтически пригодным для лечения опухолевых заболеваний.1. An antitumor composition containing combinations of taxane derivatives with a substance therapeutically suitable for the treatment of tumor diseases. 2. Композиция по п. 1, отличающаяся тем, что в качестве терапевтически пригодного вещества применяют алкилирующие агенты, антиметаболиты, веретенные токсины, эпидофиллотоксины, антибиотики, ферменты, ингибиторы топоизомеразы, различные соединения, выбираемые среди прокарбазина, митоксантрона, или координационные комплексы платины, модификаторы биологического ответа или ингибиторами факторов роста. 2. The composition according to p. 1, characterized in that alkylating agents, antimetabolites, spindle toxins, epidophyllotoxins, antibiotics, enzymes, topoisomerase inhibitors, various compounds selected from procarbazine, mitoxantrone, or platinum coordination complexes, modifiers are used as therapeutically suitable substances. biological response or growth factor inhibitors. 3. Композиция по п. 2, отличающаяся тем, что алкилирующие агенты выбирают среди циклофосфамина, ифосфамида, мелфалана, гексаметилмеламина, тиотепы или дикарбазина. 3. The composition according to p. 2, characterized in that the alkylating agents are selected from cyclophosphamine, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dicarbazine. 4. Композиция по п. 2, отличающаяся тем, что антиметаболиты выбирают среди 5-фторурацила, цитарабина и аналогов фолиевой кислоты, выбираемых из метотрексата, идатрексата и триметрексата. 4. The composition according to p. 2, characterized in that the antimetabolites are selected among 5-fluorouracil, cytarabine and folic acid analogues selected from methotrexate, idatrexate and trimerexate. 5. Композиция по п. 2, отличающаяся тем, что веретенные токсины выбирают среди алкалоидов барвинка, из синтетических или полусинтетических аналогов, или эстрамустина или таксоидов. 5. The composition according to p. 2, characterized in that the spindle toxins are selected among vinca alkaloids, from synthetic or semi-synthetic analogues, or estramustine or taxoids. 6. Композиция по п. 2, отличающаяся тем, что эпидофиллотоксины выбирают среди этопозида и тенипозида. 6. The composition according to p. 2, characterized in that the epidophyllotoxins are selected among etoposide and teniposide. 7. Композиция по п. 2, отличающаяся тем, что антибиотики выбирают среди даунорубицина, доксорубицина, блеомицина или митомицина. 7. The composition according to p. 2, characterized in that the antibiotics are selected among daunorubicin, doxorubicin, bleomycin or mitomycin. 8. Композиция по п. 2, отличающаяся тем, что ферментом является 1-аспарагин. 8. The composition according to p. 2, characterized in that the enzyme is 1-asparagine. 9. Композиция по п. 2, отличающаяся тем, что ингибиторы топоизомеразы выбирают среди камфотецина и его производных, в свою очередь выбираемых среди СРТ-11 и топотекана и производных пиридобензоиндола. 9. The composition according to p. 2, characterized in that the topoisomerase inhibitors are selected among camphothecin and its derivatives, which in turn are selected from CPT-11 and topotecan and pyridobenzoindole derivatives. 10. Композиция по п. 2, отличающаяся тем, что различные соединения выбирают среди прокарбазина, митоксантрона и координационных комплексов платины, выбираемых среди цисплатины и карбоплатины. 10. The composition according to p. 2, characterized in that the various compounds are selected among procarbazine, mitoxantrone and platinum coordination complexes selected among cisplatin and carboplatin. 11. Композиция по п. 2, отличающаяся тем, что модификаторы биологического ответа и ингибиторы факторов роста выбирают среди интерферонов и интерлейкинов. 11. The composition according to p. 2, characterized in that the biological response modifiers and growth factor inhibitors are selected among interferons and interleukins. 12. Композиция по любому из пп. 1 - 11, отличающаяся тем, что она содержит дополнительно факторы роста кроветворного типа. 12. The composition according to any one of paragraphs. 1 to 11, characterized in that it additionally contains hematopoietic growth factors. 13. Композиция по любому из пп. 1 - 12, отличающаяся тем, что она содержит 10-90 мас.% производных таксана. 13. The composition according to any one of paragraphs. 1 to 12, characterized in that it contains 10-90 wt.% Derivatives of taxane.
RU95112842A 1992-11-10 1993-11-08 Antitumor composition containing taxane derivatives RU2131250C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9213525 1992-11-10
FR9213525A FR2697752B1 (en) 1992-11-10 1992-11-10 Antitumor compositions containing taxane derivatives.
PCT/FR1993/001096 WO1994010995A1 (en) 1992-11-10 1993-11-08 Antitumour compositions containing taxane derivatives

Publications (2)

Publication Number Publication Date
RU95112842A true RU95112842A (en) 1997-10-10
RU2131250C1 RU2131250C1 (en) 1999-06-10

Family

ID=9435406

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95112842A RU2131250C1 (en) 1992-11-10 1993-11-08 Antitumor composition containing taxane derivatives

Country Status (25)

Country Link
US (13) US5728687A (en)
EP (4) EP0827745B1 (en)
JP (1) JP3974938B2 (en)
KR (2) KR100334051B1 (en)
AT (2) ATE165002T1 (en)
AU (1) AU680845B2 (en)
CA (1) CA2149055C (en)
CZ (2) CZ288033B6 (en)
DE (2) DE69330724T2 (en)
DK (2) DK0667771T3 (en)
ES (2) ES2114620T3 (en)
FI (1) FI952248A0 (en)
FR (1) FR2697752B1 (en)
GR (2) GR3026666T3 (en)
HU (1) HU223773B1 (en)
MX (1) MX9306924A (en)
NO (1) NO315027B1 (en)
NZ (1) NZ257585A (en)
PL (1) PL173951B1 (en)
PT (1) PT827745E (en)
RU (1) RU2131250C1 (en)
SK (1) SK282867B6 (en)
TW (1) TW386877B (en)
WO (1) WO1994010995A1 (en)
ZA (1) ZA938182B (en)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
FR2698871B1 (en) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
FR2729295A1 (en) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa COMBINED THERAPEUTIC TREATMENT OF HYPERPROLIFERATIVE CONDITIONS
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6011069A (en) * 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
WO1997030174A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6335201B1 (en) * 1998-03-06 2002-01-01 The Regents Of The University Of California Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility
US6740497B2 (en) * 1998-03-06 2004-05-25 The Regents Of The University Of California Method and apparatus for detecting cancerous cells using molecules that change electrophoretic mobility
US6849616B1 (en) 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
EP1003521A4 (en) * 1998-03-27 2003-07-23 Upjohn Co METHODS OF POTENTIALIZING INTRAVENOUS PHOSPHATE ESTRAMUSTINE
DE69931766T2 (en) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. ANTITUMORAL AGENTS
WO1999056742A1 (en) * 1998-05-04 1999-11-11 Auckland Uniservices Limited Chemotherapeutic treatment
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
DE69923322T2 (en) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. USE OF PROPIONYL-L-CARNITINE AND ACETYL-L-CARNITINE FOR THE MANUFACTURE OF MEDICAMENTS WITH ANTIBODY EFFECT
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6737240B1 (en) * 1999-05-25 2004-05-18 Rigel Pharmaceuticals, Inc. Methods of screening for a multi-drug resistance conferring peptide
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
PL203326B1 (en) * 1999-06-25 2009-09-30 Genentech Inc Antibody, pharmaceutical composition, conjugate, isolated nucleic acid, vector, host cell and method for antibody production
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN100381172C (en) * 1999-06-25 2008-04-16 吉尼泰克公司 Treatment of Prostate Cancer Using Anti-ErbB2 Antibodies
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
DE60042693D1 (en) 1999-08-27 2009-09-17 Genentech Inc DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
IL145636A0 (en) 2000-02-02 2002-06-30 Univ Florida State Res Found C10 carbonate substituted taxanes as antitumor agents
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
MXPA02011319A (en) * 2000-05-15 2003-06-06 Pharma Mar Sa Antitumoral analogs of et 743.
CN1447696A (en) * 2000-05-19 2003-10-08 杰南技术公司 Genetic testing assay to improve likelihood of effective response to ErbB antagonist cancer therapy
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
CA2422964A1 (en) 2000-09-22 2002-03-28 Bristol Myers Squibb Company Method for reducing toxicity of combined chemotherapies
SK287901B6 (en) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
RU2178702C1 (en) * 2001-02-21 2002-01-27 Общество с ограниченной ответственностью "Нобель" Anticancer agent
US6703400B2 (en) * 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
WO2002076459A1 (en) * 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1372571A4 (en) * 2001-03-20 2006-06-07 New Century Pharmaceuticals Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
US20020182204A1 (en) * 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
RU2284818C2 (en) * 2001-05-10 2006-10-10 Анормед, Инк. Combined chemotherapy
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
WO2003026581A2 (en) * 2001-09-26 2003-04-03 Intermune, Inc. Pharmaceutical compositions and methods for treating cancer
JP2005509650A (en) * 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ Improved use of anti-tumor compounds in cancer treatment
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US7426479B2 (en) * 2002-03-12 2008-09-16 Ncr Corporation Customer activity data system and method
US6593334B1 (en) * 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
KR20050000544A (en) * 2002-05-17 2005-01-05 아방티 파르마 소시에테 아노님 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
JP2006501205A (en) * 2002-07-30 2006-01-12 カリキオン インコーポレイテッド Ezetimibe composition and method for treating benign and malignant tumors associated with cholesterol
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
US20040229931A1 (en) * 2003-04-30 2004-11-18 Aventis Pharma S. A. 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use
CA2526278A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
JP2007523188A (en) * 2004-02-23 2007-08-16 スゲン，インコーポレイティド Treatment of abnormal cell proliferation using C-MET inhibitors and M-TOR inhibitors
GT200500155A (en) * 2004-06-16 2006-05-15 PLATINUM-RESISTANT CANCER THERAPY
NZ552159A (en) 2004-06-23 2009-12-24 Synta Pharmaceuticals Corp Bis(thio-hydrazide amide) salts for treatment of cancers
JP2008514688A (en) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル Etainacidin compounds as anti-inflammatory agents
KR101287918B1 (en) * 2004-10-26 2013-07-19 오르토 바이오테크 프로덕츠 엘.피. Pegylated liposomal doxorubicin in combination with ecteinescidin 743
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
US8148426B2 (en) 2004-11-19 2012-04-03 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
EP1819349A2 (en) * 2004-11-22 2007-08-22 King Pharmaceuticals Research and Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
HUE038768T2 (en) * 2005-02-18 2018-11-28 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP1877048A1 (en) 2005-04-15 2008-01-16 Synta Pharmaceuticals Corporation Combination cancer therapy with bis(thiohydrazide) amide compounds
CA2607890A1 (en) 2005-05-16 2006-11-23 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
EP1890537B1 (en) * 2005-06-07 2012-08-08 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
MX2008002152A (en) 2005-08-16 2008-04-19 Synta Pharmaceuticals Corp Bis(thio-hydrazide amide) formulation.
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN103110948A (en) * 2005-11-04 2013-05-22 惠氏公司 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or HKI-272
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
US8193238B2 (en) * 2006-03-08 2012-06-05 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells
CN101484807A (en) * 2006-03-31 2009-07-15 麻省理工学院 Treatment of tumors expressing mutant egf receptors
WO2007139930A2 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2007290490B2 (en) 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
SI2068880T1 (en) * 2006-09-18 2012-08-31 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
DK2175884T3 (en) * 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
EP2201141A1 (en) * 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
HRP20191005T1 (en) 2009-07-06 2019-08-23 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102643443B1 (en) 2012-11-13 2024-03-06 비온테크 에스이 Agents for treatment of claudin expressing cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP2017511376A (en) 2014-03-21 2017-04-20 アッヴィ・インコーポレイテッド Anti-EGFR antibodies and antibody drug conjugates
US9937261B2 (en) 2014-06-09 2018-04-10 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
MX2018015285A (en) 2016-06-08 2019-09-18 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates.
AU2017277916A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
UY37278A (en) 2016-06-08 2018-01-31 Abbvie Inc ANTI-B7-H3 ANTIBODIES AND DRUG AND ANTIBODY CONJUGATES
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
RU2680834C1 (en) * 2018-05-23 2019-02-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Antitumor composition of doxorubicin with atp inhibitor-dependent reverse cell transporter
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2601676B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF TAXOL AND DESACETYL-10 TAXOL
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
FR2623089B1 (en) * 1987-11-13 1990-04-27 Pf Medicament PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION OF NAVELBINE
GB8806224D0 (en) 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
MX9102128A (en) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa DERIVATIVES OF TAXANE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU2005692A (en) * 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5284865A (en) * 1991-09-23 1994-02-08 Holton Robert A Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5262409A (en) * 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) * 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5495501A (en) * 1992-09-02 1996-02-27 Fujitsu Limited Communication system including a digital roll-off filter
FR2697752B1 (en) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
FR2698871B1 (en) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
US5814658A (en) * 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
MX9307777A (en) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METHANE-TAXOLES, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
DE69330722T2 (en) 1993-12-03 2002-07-11 Infineum Usa L.P., Linden CONNECTIONS CONTAINING CARBONYL GROUPS
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP0982028A1 (en) 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US7696923B2 (en) * 2005-02-03 2010-04-13 Mexens Intellectual Property Holding Llc System and method for determining geographic location of wireless computing devices

Similar Documents

Publication Publication Date Title
RU95112842A (en) ANTITUMER COMPOSITION CONTAINING TAXANA DERIVATIVES
KR950703945A (en) ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES
CA2440160C (en) Antitumor compositions containing taxane derivatives
AU2002244877A1 (en) Antitumor compositions containing taxane derivatives
AU8452991A (en) 1-aryl-3-pyridinyl-2-propene-1-ones
CA2260266A1 (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
IL71339A0 (en) Penem compounds,methods for their preparation and pharmaceutical compositions containing them
EP0360130A3 (en) Elaiophyline derivatives, method for their preparation, their use as medicines and medicines containing them
Anton et al. Actinomycin